SML0178

ARL-17477 dihydrochloride hydrate

≥98% (HPLC)

• 同義詞: N-[4-[2-[[(3-chlorophenyl)methyl]amino]ethyl]phenyl]-2-thiophenecarboximidamide dihydrochloride hydrate
• 經驗公式（希爾表示法）: C₂₀H₂₀ClN₃S·2HCl · xH₂O
• CAS號碼: 866914-87-6
• 分子量：: 442.83 (anhydrous basis)
• MDL號碼: MFCD21608518
• 分類程式碼代碼: 12352202
• PubChem物質ID: 329825207
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 儲存條件: desiccated
• 顏色: white to beige
• 溶解度: H₂O: ≥5 mg/mL
• 起源: AstraZeneca
• 儲存溫度: 2-8°C
• SMILES 字串: O.Cl.Cl.Clc1cccc(CNCCc2ccc(NC(=N)c3cccs3)cc2)c1
• InChI: 1S/C20H20ClN3S.2ClH.H2O/c21-17-4-1-3-16(13-17)14-23-11-10-15-6-8-18(9-7-15)24-20(22)19-5-2-12-25-19;;;/h1-9,12-13,23H,10-11,14H2,(H2,22,24);2*1H;1H2
• InChI 密鑰: QOPATWWWZNTSQF-UHFFFAOYSA-N

描述

應用

ARL-17477 dihydrochloride hydrate may be used in cell signaling studies.

生化／生理作用

ARL-17477 is an nNOS specific inhibitor. The IC₅₀ against rat nNOS is 35 nM and it has 100-fold selectivity over endothelial and inducible isoforms. ARL-17477 penetrates the brain, and reduces infarct size and reduces cerebral blood flow in several different rodent models of ischemic brain injury.

特點和優勢

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

安全資訊

• 象形圖: GHS07
• 訊號詞: Warning
• 危險聲明: H302,H319
• 防範說明: P264 - P280 - P301 + P312 - P305 + P351 + P338 - P337 + P313 - P501
• 危險分類: Acute Tox. 4 Oral - Eye Irrit. 2
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable